The case for & against
Bull & Bear analysis
TrueBridge, Inc. (NASDAQ: TBRG) is a healthcare technology firm specializing in revenue cycle management (RCM) and electronic health record (EHR) solutions primarily for rural and community hospitals. The company is strategically positioned to empower healthcare providers by enhancing operational efficiencies and improving patient outcomes, particularly amidst a challenging regulatory landscape. TrueBridge leverages advanced technology partnerships, including collaborations with tech giants like Microsoft, to drive innovation in its service offerings during a time of evolving healthcare needs.
Bull says
- ↑Q4 revenue of $87.2M and full-year $346.8M (1.4% YOY growth)
- ↑Adjusted EBITDA margin up 260bps, on track for 19% annual margin
- ↑Generated $20M in free cash flow, reflecting strong liquidity
- ↑Client retention >94%, underscoring service stickiness
- ↑Sales pipeline value hit a nine-quarter high, boosting revenue visibility
- ↑High earnings yield, strong profitability factor, and positive ROE
Bear says
- ↓Retention dropped among CBO clients, threatening recurring revenue
- ↓Deals over $1M take ~6 months to go live, delaying revenue
- ↓Regulatory uncertainty around Medicaid may force budget cuts
- ↓Trend of clients insourcing RCM services could erode market share
- ↓200bps margin expansion tied mainly to cost cuts may not sustain
- ↓Weak sales growth factor, negative revision trends, and high short interest
Investment themes with TBRG
Health services for families and elective treatments
Earnings Call · Q4 2024 · Mgmt. Guidance
Transcript signals
Bull points
- In Q4, cash flow from operations was $10.3 million, up approximately $23 million compared to the prior year.
- For the full year, we generated $32.1 million in cash flow from operations compared to just $1 million in 2023.
- $15.5 million in 2024 compared to a negative $22 million a year ago, an improvement of $38 million year over year.
Bear points
- bookings in the fourth quarter was $14 million, down $7 million sequentially, primarily due to the timing of closing a few large deals worth a combined $6 million that is expected to close by the first half of 2025.
- Patient care revenue of $32.7 million decreased 6.3% compared to Q4 of last year, driven by the impact of revenues from AST and Centric in the fourth quarter of 2023.
- Patient care revenue was 2%. $123 million, down 15.4% versus prior year.